MANSCAPED ® Launches Skin Ultra™ Skincare Line and Face Buffer Pro Electric Scrubber
'Expanding into skincare was a natural evolution for us and one driven by our steadfast mission to deliver head-to-toe grooming solutions for men,' said Paul Tran, Founder and CEO of MANSCAPED. 'Skin Ultra brings our brand's legacy of trusted quality, thoughtful design, and everyday ease to the skincare space, giving guys a straightforward way to look good, feel confident, and take better care of their skin. After all, your face is the first thing people see and the first impression you make, so taking care of it shouldn't be complicated.'
MANSCAPED is a brand built on meeting men's needs in their most sensitive areas, and the skin is no exception. From advanced, expertly engineered formulations to easy and effective routines, we make self-care simple. Because men's skin is typically thicker, oilier, and more prone to irritation due to higher testosterone levels, Skin Ultra was meticulously formulated to strike the right balance between results-driven ingredients and gentle nourishment.
The Skin Ultra Lineup Includes:
Skin Ultra™ Face Wash ($19.99 USD) – A daily essential for brighter, smoother-looking skin, this gentle exfoliating cleanser removes dead skin cells while keeping your face clean, hydrated, and refreshed.
Key Features:
Lightweight, non-stripping formula – Cleanses without over-drying
Ceramide-enriched – Locks in hydration and supports a healthy skin barrier
Gentle AHA complex – Exfoliates dead skin cells, revealing brighter, smoother-looking skin
Dermatologist tested for all skin types – pH-balanced to prep skin for shaving
Paraben and sulfate free
Fresh green and light woods scent
Skin Ultra™ Brightening Serum ($24.99 USD) – This antioxidant-packed brightening complex helps illuminate your complexion, improve skin tone, and reduce the appearance of lines and wrinkles.
Key Features:
Improves skin tone – Brightens, hydrates, and evens out complexion for a refreshed, energized look
Deep hydration – Hyaluronic acid plumps and hydrates, leaving skin vibrant and healthy looking
Ceramide complex – Seals in moisture and supports your skin's natural barrier
Infused with vitamin C, licorice root, and niacinamide – Helps brighten and even out skin tone
Dermatologist tested for all skin types
Lightweight, fast-absorbing formula
Paraben free
Fresh green and light woods scent
Skin Ultra™ Face Moisturizer ($19.99 USD) – This lightweight, non-greasy moisturizer locks in hydration while improving the look and feel of your skin without the shine.
Key Features:
All-day hydration – Shea butter and ceramides keep skin refreshed from morning to night
Deeply nourishing formula – Infused with hyaluronic acid, vitamin E, and shea butter to plump and hydrate skin
Dermatologist-tested for all skin types – Gentle and effective for daily use
Shine-free, non-greasy feel – Hydrates without leaving a greasy residue
Paraben free
Fresh green and light woods scent
The Face Buffer Pro ($89.99 USD) – Engineered for men's thicker skin, this premium electric face scrubber is a powerhouse exfoliator designed to unclog pores, remove dead skin, and leave your face feeling cleaner than ever.
Key Features:
100% antibacterial silicone bristles – Gently exfoliate while deep-cleaning pores
Three cleansing modes – Pad oscillation for targeted exfoliation, sonic vibrations for deep pore cleansing, or both for the ultimate refresh
Adjustable sonic vibrations – Choose between 6,000 RPMs for a gentler cleanse or 9,000 RPMs for a more powerful clean
Deep clean in just 60 seconds – Get fresh, revitalized skin, fast
Waterproof* – Built for in-shower use and easy rinsing
Long-lasting battery – Up to 75 minutes of runtime, aka over a month of cleansing on a single charge!
Five-minute quick charge option – Low battery? No problem. Get enough power for a quick clean when you're short on time
Travel lock – Prevents accidental power-ons while on the go
Best when used together, the Skin Ultra line is curated into three easy-to-shop bundles so you can choose the routine that works best for you.
Skin Ultra™ Daily Skincare Kit ($59.99 USD) – Cleanse, exfoliate, and hydrate with this formulations-only set, featuring:
Skin Ultra™ Face Wash
Skin Ultra™ Brightening Serum
Skin Ultra™ Face Moisturizer
(Free Gift) Lip Balm 3-Pack
Skin Ultra™ Starter Kit ($109.99 USD) – A beginner-friendly bundle that makes looking good easy. It includes:
The Face Buffer Pro
Skin Ultra™ Face Wash
Skin Ultra™ Face Moisturizer
Skin Ultra™ Advanced Ki t ($139.99 USD) – Designed for men who care about the details. Go beyond the basics with this complete skincare package, which includes:
The Face Buffer Pro
Skin Ultra™ Face Wash
Skin Ultra™ Face Moisturizer
Skin Ultra™ Brightening Serum
(Free Gift) Lip Balm 3-Pack
(Free Gift) Shed 2.0 toiletry bag
The Skin Ultra skincare line and Face Buffer Pro electric scrubber are now available in the U.S., with international rollout soon to follow. Customers can shop the collection on Manscaped.com, with select products available for purchase on Amazon and in retail stores following the online launch.
Better-looking skin starts here, because you're a skincare guy now.
* IPX7 rated to protect against immersion in up to one meter of fresh water for up to 30 minutes. Learn more at www.manscaped.com/waterproof.
Founded by Paul Tran in 2016, San Diego, California-based MANSCAPED ® is the global men's lifestyle consumer brand and male grooming category creator trusted by over twelve million men worldwide. The product range includes a diversified line of premium tools, formulations, and accessories designed to introduce and elevate a whole new self-care routine for men. The collection is available globally in 38 countries on manscaped.com, on Amazon in more than 100 countries worldwide, and in major retailers including Target ®, Walmart, CVS, Best Buy, Men's Wearhouse, Jos. A. Bank, Military Exchanges, and many more internationally. For more information, visit manscaped.com or follow on Facebook, Instagram, X, TikTok, Tumblr, and YouTube.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
CloudWave Maintains SOC 2 Type 2 and HIPAA/HITECH Compliance, Reinforcing Commitment to Delivering Secure, Compliant Cloud and Cybersecurity Solutions for Healthcare
MARLBOROUGH, Mass., August 04, 2025--(BUSINESS WIRE)--CloudWave, a full-service cybersecurity and cloud services provider built exclusively for healthcare, today announced that it has successfully completed its SOC 2 Type 2 and HIPAA/HITECH examination for its Healthcare IaaS and Cybersecurity Services system. The SOC 2 audit was conducted by A-LIGN, the leading provider in cybersecurity compliance trusted by more than 4,000 global organizations to help mitigate cybersecurity risks. "At CloudWave, we are focused on providing healthcare-grade security to protect data and mitigate risk for hospitals for their public cloud, private cloud, and cloud edge," said Erik Littlejohn, president and CEO at CloudWave. "Security is paramount as our customers increasingly leverage our managed cybersecurity and cloud solutions to support daily operations. Our SOC 2 and HIPAA/HITECH compliance recognizes our commitment to using industry-standard controls and best practices to meet or exceed regulatory requirements and protect sensitive patient data and critical systems." Established by the American Institute of Certified Public Accountants (AICPA), the SOC 2 examination is designed for organizations of any size, regardless of industry and scope, to ensure the personal assets of their potential and existing customers are protected. SOC 2 reports are recognized globally and affirm that a company's infrastructure, software, people, data, policies, procedures, and operations have been formally reviewed. "Congratulations to CloudWave for completing their SOC 2 audit, a widely recognized signal of trust and security," said Steve Simmons, COO of A-LIGN. "It's great to work with organizations like CloudWave, who understand the value of expertise in driving an efficient audit and the importance of a high-quality final report." This certification demonstrates CloudWave's continued commitment to compliance and ensures customers have confidence that the required safeguards are in place to protect their data. About CloudWave CloudWave is a full-service cybersecurity and cloud services provider built exclusively for healthcare. The company protects community hospitals and health systems, and specialty healthcare providers with end-to-end solutions that combine secure hosting, IT operations, and 24/7 threat detection and response. With deep experience in cybersecurity, healthcare IT, and infrastructure, CloudWave supports over 350 hospitals and health system environments, hosting more than 140 EHR, clinical, and enterprise applications across private, public, and hybrid cloud environments. CloudWave's services span managed security, risk and compliance, disaster recovery, systems management, and cloud optimization—all delivered with a healthcare-first mindset. Powered by AI-driven security operations and supported by U.S.-based Network and Cybersecurity Tactical Operations Centers staffed 24/7 by certified professionals who understand the clinical and operational realities of healthcare, CloudWave provides a cyber-ready foundation for safe, uninterrupted patient care. To learn more, visit ABOUT A-LIGN A-LIGN is the leading provider of high-quality, efficient cybersecurity compliance programs. Combining experienced auditors and audit management technology, A-LIGN provides the widest breadth and depth of services including SOC 2, ISO 27001, HITRUST, FedRAMP, and PCI. A-LIGN is the number one issuer of SOC 2 and a leading HITRUST and FedRAMP assessor. To learn more, visit View source version on Contacts Jill ColnaSVM Public Relations and Marketing Communicationscloudwave@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Journals
an hour ago
- Business Journals
GLP-1s: Life after FDA enforcement returns
Unless you've been living on another planet over the past few years, you have heard of and probably know several people that are taking glucagon-like peptide-1 drugs or GLP-1s. These revolutionary drugs, originally developed for type 2 diabetes, have become the pharmaceutical industry's most sought-after innovation thanks to their weight-loss benefits. Brand names include Ozempic® and Wegovy®, which are based on semaglutide and owned by Novo Nordisk, and Mounjaro® and Zepboud®, which are based on tirzepatide and owned by Eli Lilly. Their commercial trajectory is unparalleled with $52 billion in global sales in 2024, $64 billion predicted for 2025, and $130 billion per year expected by 2030. Humira, the best selling drug of all time won't come close to these as it has 'only' generated around $250 billion since 2003 and is expected to generate another $9-10 billion per year for the foreseeable future. However, the road to this commercial success has been one of the more interesting ones as it has brought up FDA, patent, national, and international issues. These issues began in March of 2022 for semaglutide GLP-1s and in December of 2022 for tirzepatide GLP-1s when the FDA listed each of them on the drug shortage list. Inclusion on the drug shortage list means that the FDA has determined that the demand for a specific drug exceeds its supply and that shortage has a significant impact on public health. During the time a drug is on the shortage list, the FDA does not generally institute any enforcement actions against compounders that are making copies. Once compounders were free to make compounded versions of GLP-1s, demand surged even higher as compounders began offering these drugs. Costs to consumers plummeted from $1000/month or more for the brand name drugs to $150/month or less for the compounded versions. Overnight, an entire cottage industry was born. However, this all came crashing to a halt when the FDA declared the shortage over, thereby ending its enforcement discretion. The FDA provided a phaseout period for the compounded drugs and their compounding facilities based the drug, semaglutide or tirzepatide, and the type of compounding pharmacy. The phaseout for all of the drugs and pharmacies ended on May 22, 2025. Thus, in order for compounders to continue offering these drugs, they must be presented with a valid patient-specific prescription to prepare the medications and the medications they compound must be tailored to that individual's specific needs that prevent them from taking the brand-name version. Novo Nordisk and Eli Lilly wasted no time notifying compounders that they must cease compounding these drugs. Eli Lilly filed suits against some of the larger compounding pharmacies, Empower Pharmacy and Strive Phramacy in April 2025. These suits were filed under the Lanham Act, based on the alleged illegal compounding of tirzepatide mixed with additives like vitamin B12 and glycine and thereby misleading customers into believing these products were FDA-approved. Compounders either continued to add or began adding these ingredients in order to fall under the exceptions for compounders based on the patient's specific needs. Novo Nordisk began working with Hims and Hers Health, Inc in April after the shortage for Wegovy® was declared over. This agreement was terminated in June 2025 when Novo Nordisk alleged that Hims and Hers was not complying with the law which prohibits mass sales of compounded drugs under the false guise of "personalization" and are disseminating deceptive marketing that put patient safety at risk. Novo Nordisk is also investigating additional compounders and telehealth providers for deceptive marketing based on this 'personalization' exception. With respect to the patent issues at play, Novo Nordisk has patents on semaglutide in the U.S. and most of the world that last until 2033 while Eli Lilly's tirzepatide U.S. and worldwide patents don't expire until 2036. However, generic versions of semaglutide are on the near term horizon. How you might ask? Well, Novo Nordisk failed to pay their patent maintenance fee in Canada in 2020. This means that the patent in Canada officially expired in 2020 but has been protected under Canadian laws governing data exclusivity which prevent generics from copying the drugs until January 4, 2026. Major generic-producing companies like Sandoz and Dr. Reddy's have already announced that they will be launching generic versions of semaglutide in 2026. The impact on consumers in Canada will be felt almost immediate. Additionally, consumers in the U.S. stand to benefit from the availability of generic semaglutide as the FDA generally turns a blind eye to individuals in the U.S. receiving their medications from Canada. Thus, the result of their failure to pay this maintenance fee will extend beyond Canada into semaglutide's largest commercial market. All in all, the market for GLP-1s has changed significantly since the FDA declared their shortages over. Most U.S. compounders have now ceased large-scale GLP 1 production. However, some continue to operate under state pharmacy boards or under legal protest, challenging the FDA's interpretation of "commercially available" in compounding laws. In a sense, they contend that the demand is still higher than Novo Nordisk and Eli Lilly can address. How this will play out legally remains to be seen. Sandberg Phoenix is a full-service law firm specializing in business, business litigation, health law, products liability, and intellectual property. Tracey joined Sandberg Phoenix as a shareholder in 2023, and is Practice Group Leader of the Intellectual Property practice group. With over 25 years of experience in intellectual property law, Tracey serves clients of all sizes across industries including biotechnology, agribusiness, food, health care and life sciences. He counsels clients on patent, trademark, and copyright acquisition, licensing, enforcement issues, due diligence, prosecution, litigation and other general business matters.
Business Wire
an hour ago
- Business Wire
Clarametyx Biosciences Announces FDA Grant of Fast Track and Qualified Infectious Disease Product Designations for CMTX-101
COLUMBUS, Ohio--(BUSINESS WIRE)-- Clarametyx Biosciences, Inc. ('Clarametyx'), a clinical-stage biotechnology company developing immune-enabling therapies and vaccines to address biofilm-driven chronic respiratory diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track and Qualified Infectious Disease Product (QIDP) Designations under the Gaining Antibiotic Incentives Now (GAIN) Act for CMTX-101's use to treat people with cystic fibrosis who are affected by chronic bacterial pulmonary infections. Following the recently announced positive interim analysis results in cystic fibrosis, the Company has closed an upsized second tranche of funding associated with its Series A financing from existing investors to support ongoing pipeline activities for both therapeutic and vaccine programs. 'The receipt of both Fast Track and QIDP designations from the FDA underscores CMTX-101's potential as an innovative therapy for patients suffering from chronic respiratory conditions. We look forward to working even closer with FDA to expedite the approval of a new therapy for patients suffering from difficult-to-treat pulmonary conditions,' said David V. Richards, Chief Executive Officer, Clarametyx. 'Expanded resources and support from our valued investors enables us to advance our pipeline development efforts as we look to complete enrollment in our lead clinical study by the end of this year and continue driving our vaccine program through lead optimization activities towards a 2027 IND.' FDA's Fast Track Designation offers the potential for more frequent interactions with the FDA during clinical development and, potentially, accelerated approval and/or priority review. QIDP Designation provides incentives for the development of new infectious disease technologies, including priority review and eligibility for an additional five years of market exclusivity. These designations are intended to support the development of new therapies that address serious or life-threatening infections caused by resistant pathogens. The company's ongoing Phase 1b/2a clinical trial is evaluating CMTX-101 on top of stable, background standard of care therapy in people with CF, evaluating safety and tolerability, pharmacokinetics, immunogenicity, reduction of pulmonary Pseudomonas aeruginosa burden, and additional exploratory endpoints. A recently announced interim analysis from the first 21 participants enrolled met the pre-specified criteria to proceed, and the next portion will expand the number of participants and sites active in the trial. More information is available at ( NCT06159725). About CMTX-101 CMTX-101 is an investigational immune-enabling antibody therapy in development to address chronic respiratory disease exacerbation and lung function decline. The therapy is designed to precisely and rapidly destroy the universal underlying, pro-inflammatory structure of bacterial biofilms to undermine extracellular bacterial defenses and enable more effective antibiotic and immune intervention. Because the target is universally present across bacteria, the approach can treat a range of bacterial infections and pathogen types. The goal of treatment is to dramatically improve the effectiveness of innate immune system effectors and antibiotic therapies, thereby addressing inflammation pathways driven by the biofilm state. It is currently in development in cystic fibrosis, with opportunities to expand to other chronic respiratory disease areas including non-CF bronchiectasis (NCFB), nontuberculous mycobacterial (NTM) lung disease, and chronic obstructive pulmonary disease (COPD). About Clarametyx Biosciences Clarametyx Biosciences is combating the formidable challenge of chronic, recalcitrant respiratory disease decline through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response and antibiotic intervention. The Columbus, Ohio-based company is building a pipeline of immune-enabling therapies and vaccines, including CMTX-101, which is in a Phase 2a study for infections associated with cystic fibrosis, and CMTX-301, an anti-biofilm vaccine in early development. For more information, visit us on the web or on LinkedIn.
